CODX Advances, LLIT Makes Smart Moves, EOLS Up Over 400% Since Beginning Of May

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Co-Diagnostics Inc. (CODX)

Gained 18.92% to close Tuesday's trading at $5.28.

Co-Diagnostics is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA).

News: The Company announced advancement in its Co-Primer platform technology in multiplex tests for SNP detection, which allows for multiple targets to be identified in a single reaction without costly and time-consuming re-optimization of primers.

Recent event:

On April 5, 2018, the Company reported its financial results for the year 2017. Net loss for 2017 widened to $6.96 million or $0.63 per share from $1.93 million or $0.20 per share in 2016. Revenue for the year 2017 was $7,700, primarily licensing revenue, compared to zero revenue in full year 2016.

The Company ended the year with cash and equivalents of $3.5 million and zero long-term debt.

2. AC Immune SA (ACIU)

Gained 18.63% to close Tuesday's (June 5) trading at $9.87.

News: No news

Pipeline:

The Company's lead product candidate is Crenezumab, out-licensed to Genentech, under phase III testing for the treatment and prevention of Alzheimer's disease including the first-ever Alzheimer's disease prevention trial.

Next in the pipeline is ACI-24, a liposomal therapeutic anti-Abeta vaccine, wholly owned by AC Immune, advancing to phase II in Alzheimer's disease, and is in phase Ib testing in Down's syndrome.

The other clinical candidates include ACI-35, outlicensed to Janssen Pharmaceuticals, under phase 1b study in patients with mild to moderate Alzheimer's disease, and RO7105705, outlicensed to Genentech, under phase II study in people with prodromal-to-mild Alzheimer's disease. In addition, the Company also has a couple of preclinical drug candidates and diagnostic product candidates.

3. Lianluo Smart Limited (LLIT)

Gained 18.23% to close Tuesday's trading at $2.40.

Lianluo Smart is a professional smart service products provider, which develops, markets and sells medical wearable devices, smart devices and ecosystem platform in China.

News: No news

Recent events:

On May 14, 2018, the Company announced that its Chairman of the Board of Directors, Zhitao He purchased additional 111,500 of Lianluo Smart's Class A Common Shares ("Shares") between April 27, 2018 and May 8, 2018, following his purchase of 360,000 Shares between April 4, 2018 and April 26, 2018. He commented, "My increasing shareholding in Lianluo Smart is based on my belief in the long-term development of the Company."

4. MEI Pharma Inc. (MEIP)

Gained 16.25% to close Tuesday's trading at $4.15.

News: The Company reported encouraging data from Phase 1b dose escalation study of ME-401 in patients with relapsed or refractory follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL).

The data demonstrated a 90% response rate across all patients with relapsed or refractory FL, CLL and SL, and an 86% rate in patients with relapsed or refractory follicular lymphoma.

The Company anticipates moving into a single-agent registration study by the end of the year.

5. OncoCyte Corporation (OCX)

Gained 15.09% to close Tuesday's trading at $3.05.

News: No news

Near-term Catalysts:

-- Complete DetermaVu confirmation study in the first half of 2018. DetermaVu is OncoCyte's diagnostic test for lung cancer. -- Select final commercial platform for DetermaVu in the second half of 2018. -- Conduct R&D Validation Study of DetermaVu in the second half of 2018. -- Conduct and report results of Analytical Validation Study of DetermaVu in the second half of 2018. -- Conduct CLIA Validation Study of DetermaVu in the second half of 2018. -- Conduct and report results of Clinical Validation Study of DetermaV in the second half of 2018.

6. TherapeuticsMD Inc. (TXMD)

Gained 13.23% to close Tuesday's trading at $6.59.

News: The Company is slated to make a presentation at the Jefferies 2018 Healthcare Conference on June 6, 2018.

Recent event:

On May 30, 2018, the FDA approved the Company's IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. IMVEXXY is TherapeuticsMD's first FDA-approved drug, and will be available for commercial distribution in July.

7. Evolus Inc. (EOLS)

Gained 10.72% to close Tuesday's trading at $33.76. The stock has been hitting new highs.

News: No news

Recent events:

-- On May 16, 2018, the FDA rejected the Company's Biologics License Application for DWP-450 for the treatment of glabellar lines, also known as frown lines, in adult patients.

There were deficiencies in items related to Chemistry, Manufacturing, and Controls ("CMC") processes that led to the rejection. However, no deficiencies were related to clinical or non-clinical matters. Evolus expects to respond with a complete submission to FDA within 90 days.

-- The same day, i.e., on May 16, 2018, the Company also announced good news related to favorable completion of FDA's pre-approval inspection of Daewoong's manufacturing facility in South Korea which was purpose built for production of DWP-450.

Upcoming event:

The Company is scheduled to present at the Jefferies 2018 Global Healthcare Conference on June 8, 2018.